Core Insights - Fosun International Limited was included in Fortune China's 2025 list of "Most Admired Chinese Companies," highlighting its leadership in ESG, employee responsibility, and stakeholder value creation [1][2] - The evaluation criteria for the list emphasize a balance between profit generation and social responsibility, recognizing companies with a long-term strategic vision [2] Company Performance - Fosun International's consistent ESG efforts led to its inclusion in S&P Global's "Sustainability Yearbook 2025," ranking in the top 1% for the China Edition [4] - The company's FTSE ESG score outperformed both the global and national industry averages, maintaining its position in the FTSE4Good Index Series for four consecutive years [4] Innovation and Product Development - In the first half of 2025, Fosun's innovative drug HLX43 became the first PD-L1-targeting antibody-drug conjugate to enter Phase II clinical trials, showing strong potential in treating solid tumors [5] - Fosun Kairos promoted the accessibility of Yi Kai Da, the first CAR-T cell therapy approved in mainland China, which is now included in over 110 urban customized commercial health insurances [6] Social Contributions - Fosun Pharma's artesunate for injection has treated over 84 million patients with severe malaria globally, with over 420 million doses supplied [7] - The Rural Doctors Program has supported 25,000 rural doctors and benefited 16.34 million rural residents across 78 counties in 16 provinces [8] Future Strategy - Fosun aims to focus on core businesses, enhance innovation, and advance its globalization strategy while driving sustainable growth and creating value for stakeholders [9][10] - The company plans to refine its ESG management, respond to national strategies, and promote technology innovation while ensuring employee rights and interests [10]